Patients are Sutro’s
passion and purpose.

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. 

Our Sutro Story

Science designed to deliver ENDLESS OPPORTUNITY

Enabling a future where more is POSSIBLE.

Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience.

Explore opportunities

Join us and thrive in a team that values diversity and collaboration.

INVESTOR RESOURCES

NASDAQ: STRO

Stock Symbol

Press Releases

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations STRO-004 (tissue factor ADC) preclinical...

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., September 20, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 SOUTH SAN FRANCISCO, Calif., September 14, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company...